Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 26, 2009

Neuraltus Closes $17M Series A Financing

Neuraltus Closes $17M Series A Financing

Neuraltus closes series A financing round with three firms

  • Neuraltus Pharmaceuticals completed a $17 million series A financing round with Latterell Venture Partners, VantagePoint Venture Partners, and Adam Street Partners. Each venture firm will have a seat on Neuraltus' board of directors.

    The funding is expected to cover the costs of Phase I and II testing for Neuraltus' ALS therapy, a treatment to reduce dyskinesia in Parkinson's patients, and a drug therapy for Gaucher's disease.

    "Neuraltus offers a strong pipeline of compounds for the treatment of serious neurological diseases for which there are few if any clinical options," says James Woody, Ph. D. of Latterell Venture Partners.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »